The Connective IssueThe Fascia Institute & Treatment Center Journal
A weekly report from the corner of fascia medicine — where pain, performance, and getting back in are decided.
Unretired. And the disclosure goes at the top, not the bottom.
Last week we were backstage. This week we are in the corner — and the timing is not decoration.
Tomorrow night in Midland, Texas, Victor “Jalapeño” Hernandez fights Conrad Martinez for the WBC USA featherweight title. Ten months ago he was retired.
He did not lose a step and nobody caught him. He was 15-0 with thirteen knockouts, ranked twelfth in the world at 126 pounds, when he walked away in November 2025 — because of myofascial pain. The kind that does not appear on an MRI, does not have a name most people recognize, and does not get better because you want it to.
Read this before you read a word of the story
Victor is our patient, and The Fascia Institute is a sponsor of his professional boxing career. His name, his story, and his treatment details appear here with his written authorization. That is a real conflict of interest, and it belongs at the top of the page rather than in the fine print at the bottom, because it should change how skeptically you read what follows. Read the rest knowing it.
Now the caveat that matters more than the disclosure. There is a version of this story that says we found the machine that fixed him, and that version would be dishonest. Nine things were used on Victor across ten months. He also trained, rested, changed his loading, and had a great deal of time pass. One person getting better cannot tell you which of those things did it. The cover story says so, directly underneath the list.
What the case does illustrate honestly is different, and it is the part worth your attention: his pain had a physical explanation the whole time, and finding it took someone examining the tissue while he moved rather than photographing it while he lay still. That is not a device story. It is a diagnosis story, and it is the most common story in this newsletter.
Two things we are deliberately not publishing: which part of his body it was, and the workup he had already been through before he got to us. Those are his to share, not ours. The shape of the problem is what generalizes anyway — and the shape is the same every time.
So this week: Victor's course in the four stages it actually ran in, with the evidence behind each piece stated plainly, including where it is thin and where two trials flatly contradict each other. Then the clinical companion: what myofascial pain actually is, why it gets missed so often, and the real scientific argument about whether the “trigger point” is a thing at all.
Also, as promised in print last week: a spotlight on Hannah — who, as it happens, is the person who delivers four of the nine treatments in the cover story. And the free September OxeFit calendar has under three weeks left on it.
Gloves up. Round one.
In This Issue
- Unretired: Victor Hernandez Fights Tomorrow Night Main Event
- What Myofascial Pain Actually Is Tale of the Tape
- Spotlight: Hannah Reynolds, LPN Champion’s Corner
- Under Three Weeks Left on Free OxeFit Between Rounds
- The Wall Slide, and What Your Shoulder Blade Is Doing Speed Bag
The fight that never happened, and the one that happens tomorrow.
On October 11, 2025, Victor Hernandez was supposed to fight Conrado Martinez for the NABF featherweight title in a ring built on the infield of a minor-league ballpark in El Paso. The bout came off the card. The following month he retired. Tomorrow night he fights the same man for the WBC USA title.
Start with the part that has nothing to do with equipment.
A fighter with a structural injury has a clear path: there is a picture of the problem, there is a procedure, there is a rehab timeline. A fighter whose pain has no picture has none of that. He has an MRI that reads “unremarkable,” a physical therapist who has run out of ideas, and a growing suspicion that people think he is soft.
That is not an exotic presentation. That is Tuesday. The only unusual thing about Victor is that he had a ranking and a title shot to go back to, which made the stakes legible to everybody else.
Boxing is a soft-tissue sport treated like a head-injury sport
Almost all the medical attention boxing receives, deservedly, goes to the brain. But that is not where most of the injuries are. In a systematic review and meta-analysis of boxing epidemiology studies published this century, the pooled breakdown was 30.2% soft-tissue contusion, 21.4% laceration, 15.3% sprain and muscle or ligament injury, 12.3% concussion, and 11.4% fracture. Soft tissue is the single largest category and the one with the least infrastructure around it.
The load is also relentless and one-sided. In the Great Britain Olympic squad tracked prospectively from 2005 to 2012, the number of hand and wrist injuries sustained in training was about the same as in competition. That is a statement about cumulative exposure, not about single traumatic events — and cumulative exposure is exactly what fascia responds to.
Fascia is densely supplied with free nerve endings, which makes it a pain generator in its own right rather than a passive wrapper. It can actively stiffen. And in chronic pain it changes in ways ultrasound can see: connective tissue measurably thicker, more echogenic, and worse at sliding than in pain-free controls.
None of that appears on a standard MRI report. An MRI is a still photograph taken while you lie motionless in a tube — excellent at anatomy, nearly blind to behavior. Whether layers slide. Whether a nerve is tethered. Whether a structure hurts when you press it and the patient says that's it, that's my pain. Which is why the first thing we did with Victor was not a treatment.
The four stages, in the order they have to happen
Nine things were used, and they were not nine attempts at the same job. They sit in four stages, and the order matters more than the list. You cannot release tissue you have not located, and you cannot expect a release to hold if the athlete never loads it afterward. Nobody gets all nine as a package; what you get follows what the examination shows.
| Stage | What we did | What the evidence actually supports |
|---|---|---|
| 1 · Find it Fascial Mapping® |
A 488-point diagnostic ultrasound examination of the whole body, performed by a physician, scoring tissue quality and glide point by point and comparing side to side — while the athlete contracts, relaxes and rotates. | This is the step that produced the first actual explanation Victor had been given, and everything downstream followed the map rather than a protocol. Stated honestly: it is a clinical examination, not a diagnostic test with published sensitivity and specificity. What the literature does support is the premise — that connective tissue thickness, echogenicity and glide differ measurably in chronic pain, and that these are dynamic properties a still image cannot capture. |
| 2 · Change the tissue Hydrofascia Release™ |
Ultrasound-guided fascial hydrodissection: a thin needle at the exact interface identified on the map, and fluid used to separate planes that have scarred together or to free a nerve tethered to the fascia it should glide through. | Stronger than most people assume. Dr. Courseault first published the technique for chronic hamstring injury, and published it again for a fascial adhesion strangling the ulnar nerve of a Division I pitcher — released under ultrasound, pitching a full game four days later, symptom-free at seven months. An independent Japanese group has since replicated the hamstring application in a small series. And for nerves specifically there is a randomized, double-blind, controlled trial: perineural 5% dextrose beat control in carpal tunnel syndrome out to six months. What is still missing is a randomized trial of the muscle and tendon application — that rests on published case work and independent replication, not on an RCT. |
| 2 · Change the tissue Dextrose prolotherapy |
Where release is the wrong answer — a ligament or tendon gone lax rather than stuck — the goal inverts. Dextrose provokes a repair response to tighten tissue rather than free it. | The most relevant evidence for a fighter comes from kicking-sport athletes: a series of elite male athletes with chronic groin pain treated with dextrose prolotherapy, most returning to unrestricted sport — though that was a case series with no control group, and it should be read as one. The broader systematic-review evidence for chronic musculoskeletal pain is favorable but heterogeneous. The mechanism is multifactorial rather than the simple “irritant” story it is usually sold as, and the cell-culture work most often cited for it was done in kidney fibroblasts, not tendon. Plausible mechanism, not proven mechanism. |
| 3 · Turn it down Shockwave |
Acoustic pressure waves delivered through the skin to the tissue target. | The strongest evidence of anything in stage three, for this indication. A systematic review and meta-analysis of randomized clinical trials — 27 studies, 595 patients in the shockwave arm — found it effective for pain and function in myofascial pain syndrome, against both control and therapeutic ultrasound. The honest caveat from a 2025 scoping review is that protocols across the literature are wildly inconsistent in energy, impulse count, and even in how myofascial pain is diagnosed. So “shockwave works” is better supported than any specific dose. Note also that its record in tendinopathy is much weaker — a 2026 pooled analysis in Achilles tendinopathy found no clinically meaningful benefit over sham. Different indication, different answer. |
| 3 · Turn it down HUMAN TECAR |
Capacitive and resistive energy transfer — a radiofrequency current that raises tissue temperature at depth. | Adding TECAR to stretching and medication for upper-trapezius myofascial pain produced significantly lower pain scores than conventional treatment alone in a randomized clinical trial. Directly relevant to a fighter: three sessions of TECAR plus static stretching improved hamstring length more than ultrasound plus the same stretching in male athletes. The systematic review is positive across musculoskeletal disorders while noting that only two of thirteen included studies carried a low risk of bias. |
| 3 · Turn it down Red light |
Red and near-infrared light applied to muscle, hypothesized to act through mitochondrial and inflammatory pathways. | The timing detail is the part usually gotten wrong. A meta-analysis of randomized controlled trials in athletes found light delivered before exercise improved lower-limb muscle strength at 24, 48 and 96 hours and at eight weeks, with lower soreness and lower creatine kinase and interleukin-6. Most of the benefit in the literature comes from pre-loading, not from lying under a panel afterward. The counterweight, and it is a real one: a 2024 review across twelve systematic reviews concluded the outcomes are beneficial but the primary evidence is low quality, and that no peer-reviewed guideline for laser use in athletic performance exists. Other meta-analyses have found no strength effect at all. |
| 3 · Turn it down PEMF |
Pulsed electromagnetic fields, FDA-cleared for bone non-union since 1979, used here for pain and recovery between hard sessions. | Be careful with the claims. In a meta-analysis of eight randomized trials in knee osteoarthritis, PEMF improved physical function but showed no advantage over control for pain or stiffness. A 2026 systematic review of randomized trials in soft-tissue injury specifically found only four eligible trials — a thin base to generalize from. Well tolerated, and not a substitute for the work in stage two. |
| 3 · Turn it down Microcurrent |
Sub-sensory electrical current, used for soreness between camps. | The evidence here is genuinely split and we are not going to pretend otherwise. A systematic review of four randomized and five non-randomized trials found significant improvement in shoulder and knee pain versus sham, with one minor adverse event across 281 participants — an excellent safety profile. A frequency-specific protocol markedly reduced delayed-onset soreness versus sham at 24, 48 and 72 hours. But an earlier double-blind comparison of conventional microcurrent found no benefit over sham for soreness or range of motion. Read together: the parameters appear to matter more than the modality. This belongs in the cheap, safe, possibly-helpful tier — not the tier that changes a career. |
| 4 · Reload AlterG |
A lower-body positive-pressure treadmill: an air chamber seals at the waist and lifts, letting an athlete run at a precise fraction of body weight so roadwork can restart before the tissue tolerates full impact. | Used in return-to-run programs after bone stress injury, Achilles rupture and major knee surgery, with better control over progressive reloading than pool running or harness systems. Two honest limits: reduced weight-bearing measurably changes stride mechanics, mostly by lengthening flight time — which is why it is a bridge and not a destination — and it does not build aerobic capacity better than normal training does. For a boxer the point is simple: keep the engine while the tissue heals. |
| 4 · Reload OxeFit |
A robotic resistance platform that measures force on both sides independently, so left-right asymmetry becomes a number instead of a hunch, and that can load the eccentric phase heavier than the concentric. | The stage that decides whether any of the rest holds. Progressive resistance training is one of the best-evidenced interventions in all of rehabilitation, eccentric-emphasis work drives distinct adaptations in strength and tissue tolerance, and real-time force feedback measurably increases output within a session. Two caveats we keep in front of athletes: there is no validated asymmetry threshold that tells you when you are safe, and passing a return-to-sport test battery has not been shown to prevent reinjury. Numbers inform the decision. They do not make it. |
The part most clinics would leave out
What the evidence actually supports, tiered honestly
Strongest: shockwave for myofascial pain (meta-analysis of randomized trials), perineural dextrose hydrodissection (randomized, double-blind, controlled, six-month follow-up), and progressive resistance and eccentric loading (decades of trials across rehabilitation).
Promising but thinner: fascial hydrodissection for muscle and tendon, which rests on Dr. Courseault's original published work plus independent replication in small series rather than on a randomized trial; TECAR; and photobiomodulation, where the direction of effect is consistent but the primary studies are small and of low quality.
Weakest: PEMF, where the best musculoskeletal meta-analysis found benefit for function but not for pain, and microcurrent, where trials directly contradict each other depending on the parameters used. These are safe, tolerable adjuncts. They are not the reason anyone gets back in a ring.
No evidence for the devices themselves: there are no published clinical trials on the OxeFit, or as devices on the specific machines we use. The evidence supports the training principles they deliver — measured progressive load, eccentric emphasis, unloaded gait — not the hardware brand.
And the honest limit of the whole story: this is one athlete who received nine things over ten months. There is no way to know which component did the most work, and no way to rule out the training he did, the time that passed, or his own belief that he was fixable. A single case cannot separate a device from the rehabilitation program, the change in training load, ordinary healing, regression to the mean, expectation, or the plain effect of finally being taken seriously by somebody. One person getting better is not evidence that a protocol works. It is a reason to look carefully at the next person who walks in with unexplained pain and a stack of normal scans.
What we did not do
We did not clear him to fight. Medical clearance for a professional bout belongs to the athletic commission, not to us. We also did not make him a better boxer. What we did was find a physical explanation for pain that had been treated as unexplainable, change the tissue that was generating it, and then reload him carefully enough that he trusted his own body under load again.
He did the rest, and the rest was the hard part.
Who this story is actually for
Almost none of you have a title fight tomorrow. You have a job, a season, a kid to carry, a shift to work. The transferable part is not the equipment list. It is this: pain that imaging cannot explain is not the same as pain that has no explanation. If you have been discharged from care because your scan was clean, you were not given an answer. You were given the absence of one.
And the reason this is in the newsletter is not that treating a fighter is unusual for us. It is that the version of this story we see most often ends with the athlete quietly stopping. Somebody in that position is reading this. That is who it is for.
Disclosure: Victor Hernandez is a patient of The Fascia Institute and Treatment Center, and The Fascia Institute is a sponsor of his professional boxing career. His name, story, and treatment details appear here with his written authorization. Individual results vary and one patient's outcome does not predict yours; nothing here is a guarantee of any result. Educational information only, not medical advice, diagnosis, or treatment. The Fascia Institute did not provide medical clearance for competition — clearance for a professional bout is determined by the relevant athletic commission. None of the treatments described is FDA-approved for myofascial pain; these are cleared devices and off-label injection techniques used at physician discretion, and they are not appropriate for every cause of pain. Injection procedures carry risks of bleeding, infection, and nerve injury, and dextrose is a glucose load worth discussing if you have diabetes. Energy-based treatments are generally avoided over metal implants and surgical hardware; over implanted electronics including pacemakers, defibrillators, spinal cord stimulators, and insulin or intrathecal pumps; in pregnancy; over active malignancy in the treatment field, active infection, or acute thrombosis; in epilepsy; in significant cardiovascular disease or impaired temperature regulation; and where sensation is reduced. And because it matters for many of our patients: heat can trigger mast cell degranulation and is poorly tolerated in POTS and dysautonomia — if that is you, tell us, and we will use non-thermal settings or a different tool.
What myofascial pain actually is, and the argument about it.
It ended a fighter's career, and most people have never heard of it. Part of that is that it is genuinely hard to diagnose. Part of it is that the field cannot agree on what it is.
Here is the definition in use: myofascial pain is regional muscle pain — one muscle or one muscle group, not the whole body — with a tender spot that reproduces the patient's pain and often refers it somewhere else. A shoulder problem that shows up in the arm. A hip problem felt in the groin. A neck problem that arrives as a headache.
Everything I just wrote is clinically useful and none of it is a settled biological entity. I would rather you hear that from me than find it later and wonder why I did not mention it.
Why it gets missed
There is no test on the standard menu
No imaging finding, no blood marker, no validated diagnostic study. The scan comes back normal, and normal gets translated as nothing wrong. What ultrasound can show — and this is the premise our whole examination rests on — is that connective tissue in chronic pain is measurably thicker, more echogenic, and worse at sliding than in pain-free controls. Those are dynamic properties. A still image taken while you lie motionless cannot capture them, and a dynamic exam is not the same thing as a validated diagnostic test. Both of those sentences are true and we say both.
It impersonates a pinched nerve
Referred muscle pain does not respect the map of the nerve roots, which is exactly why it fools people. In one series of 170 patients sent for electrical testing on suspicion of a lumbosacral nerve problem, nearly one in three had a muscle or tendon condition instead — myofascial pain, IT band and hip pain, or plantar fasciitis. Not one in three had myofascial pain specifically, but one in three had something the nerve workup was never going to find.
Finding it with fingers alone is unreliable
This is the uncomfortable one, and it is the reason we scan instead of guessing. Pooled across studies, agreement between two trained examiners palpating for the same trigger point was κ = 0.45 — “fair,” below any threshold you would accept for a clinical test. What did hold up better: localized tenderness, and the patient recognizing the pain as theirs. What held up worst: the “taut band” and the twitch response — the two findings the classic model leans on hardest. Palpation is a good way to ask a question. It is a poor way to answer one.
Nobody knows how common it is
Published prevalence in pain and general clinics ranges from 20% to 95%, which is not a statistic so much as a symptom of the criteria problem. The most concrete figure is old and small: of 54 primary-care patients presenting with pain, 30% met criteria — and the authors' conclusion was that physicians rarely recognized it.
The argument, stated fairly
You will read everywhere that a trigger point is a “knot” — a band of muscle fibers stuck in contraction. That model has been challenged for a decade, and in 2025 it took a real hit. A study of 49 patients with active upper-trapezius trigger points found the affected side measurably thicker and stiffer than the healthy side, and measurably less so after needling, with pain scores falling. Then they biopsied five of them. They found muscle fiber atrophy and fatty change, and no contraction knots. The authors' own reading: what you feel under your fingers is composite tissue stiffness, not a discrete lesion.
A prominent critique in the rheumatology literature goes further, arguing the trigger point as a pathological entity has no scientific basis and that the phenomena are better explained by known nervous-system sensitization. Defenders of the classic model published a detailed rebuttal. That exchange has not been resolved. Meanwhile the biochemical work most often cited as proof — elevated inflammatory chemicals and a strikingly acidic pH inside trigger points — has never been independently replicated and was formally challenged in 2023, partly because the reported pH was low enough to denature protein in living tissue.
Two 2025 papers in the physical therapy literature put it plainly: the condition remains controversial because its etiology, diagnostics, and proposed mechanisms rest on frameworks with limited scientific rigor, and the diagnosis is exposed to a circularity problem — if a tender muscle is both the test and the diagnosis, the label can be applied to almost anything. Under the current international classification, much of what gets called myofascial pain sits inside chronic primary musculoskeletal pain, described mechanistically as nociplastic — a nervous system amplifying a signal rather than a structure that is broken.
None of this means the diagnosis is useless. It means it is a clinical description rather than a proven pathology — which changes what should follow from it, and mostly points toward loading, movement, and calming a sensitized system rather than toward chasing a lesion.
Is it myofascial pain, fibromyalgia, or a tendon?
These three get confused constantly, and the confusion has consequences, because what helps each of them is different.
| Myofascial pain | Fibromyalgia | Tendinopathy | |
|---|---|---|---|
| Where it is | Regional — one muscle or group | Widespread — criteria require pain in at least 4 of 5 body regions, both sides, above and below the waist | Focal, at one tendon or its attachment |
| What provokes it | Pressure on the tender spot reproduces the patient's own pain, often referred elsewhere | Diffuse tenderness without a characteristic referral pattern | Loading the tendon — a calf raise, a hop, a decline squat |
| Timing pattern | Constant or activity-related | Migratory, at least 3 months, with fatigue, unrefreshing sleep, cognitive symptoms | Hurts during activity, settles after, worse the next morning |
| Formal criteria | None validated — expert consensus only (2 of 3: taut band, tender spot, referred pain) | ACR 2016 criteria, scored. The old 11-of-18 tender-point exam is obsolete | Clinical: localized tendon pain on loading, focal tenderness, sometimes thickening |
| First line | Graded exercise and loading; local treatment as an adjunct | Centrally directed management, graded exercise, and medication aimed at the nervous system | Progressive loading. Not rest |
One correction to that table before anyone uses it as a fork in the road: the 2016 fibromyalgia criteria state explicitly that the diagnosis is valid regardless of other diagnoses. These conditions co-occur, frequently, in the same patient. A clean either/or is the wrong mental model — and the co-occurrence is a large part of why differentiating them fails in practice.
And what the treatments really do
Since I put my own equipment through this above, the same treatment for the things everybody asks about:
- Exercise — combined stretching and strengthening produced a statistically significant short-term pain reduction in pooled data, around 1.2 points on a 10-point scale against minimal or no intervention. Modest. Also the most durable thing on this list, and the cheapest.
- Dry needling — beats sham for immediate pain in small trials. But in a sham-controlled trial of 77 neck-pain patients followed a full year, adding dry needling to manual therapy and exercise produced no difference at any time point, and a 2025 sham-controlled shoulder trial of 121 patients missed its primary outcome at one year. The accurate summary: short-term relief, sham-equivocal, no added value on top of good physical therapy.
- Trigger point injection — no agent has been shown superior to placebo or to another agent. In a randomized emergency-department comparison, plain saline was non-inferior to lidocaine plus steroid, which suggests the needle is doing much of the work.
- Botulinum toxin — the clearest negative here. A Cochrane review of 4 placebo-controlled studies in 233 participants was inconclusive, with 3 of 4 showing no significant difference in pain.
- Manual therapy — helps patients in clinic every day, and in a network meta-analysis was not statistically better than conventional therapy or placebo, attributed to small samples and inconsistent quality. Both of those sentences are true.
If that list reads as deflating, read it again with the fighter in mind. The evidence is weak for the procedures and decent for the loading, which is precisely why the answer for Victor was never going to be a machine. It was a diagnosis, then a plan, then months of work.
Educational information only, not medical advice, and not a basis for diagnosing yourself or anyone else. Regional muscle pain can also be caused by conditions that need different care entirely — nerve compression, inflammatory arthritis, infection, fracture, thyroid and metabolic disease, and rarely malignancy. New, severe, night-waking, or progressive pain, pain with fever or weight loss, and any pain with weakness, numbness, or bowel or bladder change needs evaluation, not a self-treatment plan.
Four of the nine treatments in this issue are hers to deliver.
Hannah Reynolds, LPN · FLIP Program Coordinator
The cover story lists nine things across four stages. Stage three has four of them in it — and in this practice those four usually come from the same pair of hands.
I promised you Hannah last week, and I have been looking forward to it, because her role is the one patients feel most and hear about least.
Hannah is a licensed practical nurse, and she performs our shockwave, TECAR, red light, and PEMF treatments under my supervision. Go back and read stage three of the table above. Those are her four.
She also coordinates FLIP — the FIT Lipedema and Inflammation Program. Which, if you have been reading this issue from the top, should sound familiar. Lipedema is a painful connective-tissue and fat disorder that affects women almost exclusively, and it is routinely dismissed as ordinary weight gain for years before anybody names it. Different condition, same shape of problem as Victor’s: real, physical, and invisible to the test everyone reached for first.
Why that is not a small thing
Here is what does not come across in a table: every one of those modalities is operator-dependent. The device does not treat anybody. A shockwave head placed two centimeters off target is a different treatment. TECAR run thermally on someone who should have had it non-thermal is a different treatment, and for some of our patients a worse one. Red light delivered after a session instead of before it is, on the best available evidence, largely the wrong dose at the wrong time. The machine is identical in all four cases. The outcome is not.
And then the part that genuinely keeps me from worrying: she is the last line on the contraindication list. Scroll back to the fine print under the cover story — metal implants and surgical hardware, pacemakers and defibrillators, spinal cord stimulators, insulin and intrathecal pumps, pregnancy, epilepsy, reduced sensation. Heat and mast cell degranulation. Heat and POTS. That list is not decoration and it is not the physician's alone. It belongs to whoever is standing at the machine, and it only works if that person actually asks, actually remembers, and actually notices when a patient who said they were fine has gone pale and quiet.
She is also the continuity. A multi-month program with injections, device sessions, loading progressions and reassessments is not a treatment — it is a logistics problem wearing a treatment's clothes. Someone has to keep it moving when a week gets missed, notice when a patient has quietly stopped coming, and carry the clinical thread from one visit to the next. When that person is good, the plan holds. When there is no such person, the plan degrades into a series of appointments.
I asked her what the work is actually like.
Working at FIT has given me the opportunity to be part of something that truly makes a difference in people’s lives. I’m grateful to work alongside a team that is constantly learning, growing, and finding ways to better care for our patients. I love being able to connect with our patients, support them throughout their journey, and be part of a team that genuinely cares about what we do.
— Hannah Reynolds, LPN
I want to sit on one phrase. Support them throughout their journey.
That is a word patients use about themselves constantly and clinicians almost never use back. Nobody arrives here after one bad week. They arrive after years — the appointments, the normal imaging, the specialist who was sure and then was not. By the time someone reaches a device in our building they have usually already been through a great deal, and how the twelfth week of a program feels depends almost entirely on the person running it.
Thank you, Hannah. Half of what patients call good care is really continuity, delivered carefully, by someone who was paying attention. That has a name in this building.
Nineteen days left on the free calendar.
OxeFit assessments cost nothing through the end of September — New Orleans and Beverly Hills both. Slots do not carry into October, and the back half of the month is where they run out.
Victor had his numbers taken on this equipment, so let me be exact about what it is and is not for. It measures. It does not predict.
What it gives you is objective: how you produce and absorb force, strength, balance, side-to-side symmetry, movement quality — recorded rather than estimated by feel, which is worth something, because feel is unreliable and gets worse when you are tired. And it gives you a baseline you can re-check, which is the only way to know whether something changed.
What it does not give you is a forecast. No movement or strength screening test in sports medicine has ever met the standard for predicting who will get injured, and a normal assessment is not medical clearance. Anyone selling you an assessment as injury prevention has skipped that literature.
- Anyone coming back from an injury — objective proof of where recovery actually stands, rather than how it feels on a good day.
- Athletes in season — force and symmetry numbers are exactly what you cannot get by feel.
- Hypermobility and connective-tissue patients — a stability and control baseline that is notoriously hard to capture any other way.
- Anyone over 40 — the earliest strength and balance changes are the ones worth catching early.
Pick your city and take a slot — first come, first served.
September 1–30, 2026 · by appointment and subject to availability. An assessment is not a diagnosis, is not medical clearance, and does not predict injury.
Beverly Hills
The Fascia Institute LA
Same assessment, same offer, on the West Coast.
Book Free OxeFit →Stand against a wall and watch your shoulder blades.
Sixty seconds, no equipment, and it looks at something boxers, throwers, swimmers, and desk workers all have in common: whether the shoulder blade moves the way it is supposed to.
A quick note on why this one, this week. In a study of 72 elite boxers, 38 of them — nearly 53% — had scapular dyskinesis, meaning altered movement of the shoulder blade. And among those boxers, the ones with obvious dyskinesis reported measurably more neck disability on the non-dominant side. The shoulder blade is the platform the whole punch is thrown from. If the platform is moving oddly, the neck and the shoulder pay for it.
How to do it. Stand with your back to a wall, heels a few inches out, and let your head, upper back, and tailbone rest against it. Bring your arms up into a goalpost position — elbows bent, backs of the hands toward the wall at about shoulder height. Now slide the hands slowly up the wall as far as they will go while keeping the backs of the hands, the elbows, and your low back in contact. Come down slowly. Five to eight repetitions.
What you are looking for. Three things. Whether the backs of your hands stay on the wall or peel off partway up. Whether your low back arches away from the wall to buy you extra range. And whether the two sides feel and look the same — if you can film it from behind, watch for one shoulder blade winging off the ribcage or hiking toward the ear while the other does not.
Boxers: this is the same overhead path your guard travels, done slowly enough to be honest about it.
What it is not. Not a diagnosis, not a screening test, and not a prediction. Visual assessment of shoulder blade movement has its own reliability problems, and asymmetry does not tell you that anything is going to be injured — that literature is inconsistent and screening tests have a poor record of predicting anything. A restriction here can come from the shoulder, the ribs, the thoracic spine, the neck, or simply from being stiff this morning. Treat it as a prompt to look, not a verdict.
Educational description of a movement test, not medical advice. Skip it if you have an acute shoulder or neck injury, recent surgery, or pain on raising the arm. Stop at the first pinch — forcing overhead range against a wall is a good way to irritate a shoulder. If you are hypermobile, stay well inside the range where you feel controlled rather than pushing for end range, which is a common way to provoke a shoulder subluxation or a flare.
Missed last week? Catch up on Vol. XIV — low-dose naltrexone and what the evidence actually supports, why in-season athletes reach for TECAR, and a spotlight on Irina Parau in Beverly Hills.